Abstract:BACKGROUND & AIMS: Wilson disease is an autosomal recessive disorder that impairs copper homeostasis and is caused by homozygous or compound heterozygous mutations in ATP7B, which encodes a copper-transporting P-type ATPase. Patients have variable clinical manifestations and laboratory test results, resulting in diagnostic dilemmas. We aimed to identify factors associated with symptoms and features of Wilson disease from a large cohort, over 15 years. METHODS: We collected data from 715 patients (529 with symptoms, 146 without symptoms, and 40 uncategorized) and a genetic confirmation of Wilson's disease (mean age of diagnosis, 18.84 years), recruited from 3 hospitals in China from 2004 through 2019. We analyzed clinical data along with serum levels of ceruloplasmin (available from 636 patients), 24-hr urinary copper excretion (collected from 131 patients), Kayser-Fleisher rings (copper accumulation in eyes, with neurologic data from 355 patients), and magnetic resonance imaging (MRI) abnormalities. Differences among the groups were analyzed using 1-way analysis of variance followed by Tukey multiple comparison test. ESULTS: Of the 529 patients with symptoms, 121 had hepatic features, 355 had neurologic features, 28 had osteomuscular features (premature osteoarthritis, skeletal deformities, and pathological bone fractures), and 25 had psychiatric symptoms. Age of onset was significantly younger in patients with hepatic (16.94 +/- 1.03 years; P = .0105) or osteomuscular features (13 +/- 1.33 years; P = .0001) than patients with neurological features (19.48 +/- 0.46 years). Serum levels of ceruloplasmin differed among asymptomatic patients and patients with osteomuscular or neurologic symptoms of Wilson disease. Serum levels of ceruloplasmin ranged from 18.93 mg/L to approximately 120.00 mg/L (quantiles of 0.025 to approximately 0.975). Fifty-one of 131 patients (39%) had urinary copper excretion levels below 100 mu g/24 hr; there was significant variation in levels of urinary copper excretion between patients older than 14 years vs 14 years or younger. Of the 355 patients with neurologic features, 244 patients (69%) had abnormal findings from MRI and Kayser-Fleisher rings; only 1 patient with abnormal findings from brain MRI was negative for Kayser-Fleisher rings. CONCLUSIONS: Serum level of ceruloplasmin, 24-hour urinary copper excretion, and Kayser-Fleisher rings can be used to identify patients who might have Wilson disease. Patients with serum levels of ceruloplasmin below 120 mg/L and children with urinary copper excretion above 40 mu g should undergo genetic testing for Wilson's disease. Patients with movement disorders and brain MRI abnormalities without Kayser-Fleisher rings are not likely to have Wilson disease.

Study on different pathogenic factors in different disease stages of patients with Wilson disease

Population Screening and Diagnostic Strategies in Screening Family Members of Wilson’s Disease Patients

Microstructural and functional impairment of the basal ganglia in Wilson's disease: a multimodal neuroimaging study

Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease

Multi-omics study unravels gut microbiota and metabolites alteration in patients with Wilson's disease

Research progress in stem cell therapy for Wilson disease

Effect of Decoppering Therapy on Immune Function in Wilson's Disease

Exploration of TCM syndrome types of the material basis and risk prediction of Wilson disease liver fibrosis based on 1H NMR metabolomics

Does Gut Microbiome have an Effect on Wilson’s Disease Phenotype?

Diffuse fibrosis, coronary microvascular dysfunction and systolic dysfunction in Wilson disease

Advance in the Pathogenesis and Treatment of Wilson Disease

Identification of potential modifier genes in Chinese patients with Wilson disease

Wilson Disease: Identification of Two Novel Mutations and Clinical Correlation in Eastern Chinese Patients

Neuroimaging Correlates with Clinical Severity in Wilson Disease: A Multiparametric Quantitative Brain MRI

The Role of Glia in Wilson's Disease: Clinical, Neuroimaging, Neuropathological and Molecular Perspectives

Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson’s Disease

Extensive Disturbances of Intracellular Components and Dysfunctions of Biological Pathways in the Brain Tissues During Prion Infection — China’s Studies

Topographical metal burden correlates with brain atrophy and clinical severity in Wilson's disease

Altered cortical functional networks in Wilson's disease: A resting-state electroencephalogram study

A clinical study showing the expression characteristics of cuproptosis markers in cases with Wilson disease

Exploring the impact of gut microbiota on liver health in mice and patients with Wilson disease